TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.900nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.900nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 6nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 6nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 6.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 6.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair